| Chairman |
|
Ji Jianxin |
| Business Nature |
| 醫療保健 (Health Care) |
| Board Members |
Chairman, Chief Executive Officer & General Manager: Ji Jianxin
Executive Director: Yang Xiangyu, Wu Zhen, Zhang Yao
Non-executive Director: Geng Xueli, Du Jiangbo, Wang Junfeng, Zhang Zhiyong
Independent Non-executive Director: Wong Chi Wing Jovi, Jiang He, Lin Fangzhu, Liu Zhe(formerly known as Liu Jifang).
|
| Principle Business |
|
The Group is primarily engaged in biopharmaceutical business, focused on treatment of autoimmune, metabolic and oncology diseases. |
| Major Shareholders |
| Ji Jianxin & ASSO | 34,493,443 | H Sh | 46.87% | 46.87% | 2026/06/23 | | SDIC VC Fund (Shanghai) of Technology Transfer and Commercialization | 5,520,100 | H Sh | 7.50% | 7.50% | 2026/06/23 | | Suzhou Junlian Xinkang Venture Capital Partnership | 4,246,253 | H Sh | 5.77% | 5.77% | 2026/06/23 | | Huada (Chongqing) Private Equity Investment Fund Management Co., Ltd. | 3,999,969 | H Sh | 5.43% | 5.43% | 2026/06/23 |
|
|
|
|
|